Q-VANT operates two manufacturing facilities in Santiago and Los Angeles, Chile, specializing in the purification and fractionation of saponin adjuvant substances. These facilities are equipped with large-scale production capacity to meet the global pharmaceutical demands of saponin adjuvants and can be readily expanded for increased capacity.
Facilities for Industrial Volume
Affordable and stable cost
Q-SAP technology allows the obtention of pure molecules from varied quillaja biomass, at affordable cost for public vaccination programs, emancipating from the limited availability, the high and volatile cost of quillaja bark.
Los Angeles manufacturing facilities (CL)
- Manufacturing of starting material and veterinary adjuvant.
- Near the biomass harvesting locations.
- Employs Q-SAP Technology.
Santiago manufacturing facilities (CL)
- Manufacturing of saponin fractions.
- Manufacturing of pure saponins.
- Compliance with Good Manufacturing Practices (GMP) for pharmaceutical excipients (EXCiPACT certified process).
- Capabilities for fractionation of specific molecules
- Employs Q-SAP Technology.
Santiago R&D facilities (CL)
- GMP manufacturing of saponin fractions
- Research and development for saponin adjuvants formulations
- Development of manufacturing processes.
- Capabilities for purification, fractionation, characterization, formulation, and biological exploratory studies.
